Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Hortobagyi, Gabriel N., Stemmer, Salomon M., Burris, Howard A., Yap, Yoon-Sim, Sonke, Gabe S., Hart, Lowell, Campone, Mario, Petrakova, Katarina, Winer, Eric P., Janni, Wolfgang, Conte, Pierfranco, Cameron, David A., André, Fabrice, Arteaga, Carlos L., Zarate, Juan P., Chakravartty, Arunava, Taran, Tetiana, Le Gac, Fabienne, Serra, Paolo, O’Shaughnessy, Joyce·2022·New England Journal of Medicine
DOI 10.1056/nejmoa2114663

Cited by (760)

Items 201–300 of 760

  1. Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial
    Aniek E.M. Schouten, Anouk E. Hiensch, Geert Frederix, Evelyn M. Monninkhof, Martina E. Schmidt, Dorothea Clauss, Nadira Gunasekara, Jon Belloso, Mark Trevaskis, Helene Rundqvist et al. · 2025 · Journal of Clinical Oncology
  2. Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of view
    Woong Ki Park, Seok Jin Nam, Seok Won Kim, Jong Han Yu, Se Kyung Lee, Jai Min Ryu, Byung Joo Chae, Dong Seung Shin, Jin Seok Ahn, Yeon Hee Park et al. · 2025 · European Journal of Surgical Oncology
  3. Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer Therapy
    Mohammed Alrouji, Mohammed S. Alshammari, Saleha Anwar, Kumar Venkatesan, Anas Shamsi · 2025 · Cancers
  4. Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
    Hamdy A. Azim, Hagar Ibrahim Elghazawy, Kyrillus Samaan Shohdy, Shaimaa Lasheen, Mahmoud Elghazawy, Ramy Mohamed Ghazy, Dalia Abdelnasser, Loay Mohamed Hassan Kassem · 2025 · JCO Precision Oncology
  5. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
    Elisabeth M. Jongbloed, Noor Wortelboer, Vanja de Weerd, Corine M. Beaufort, Kirsten Ruigrok-Ritstier, Mai N. Van, Jaco Kraan, Annette A. van Zweeden, Annemieke van der Padt‐Pruijsten, Lisanne C. Hamming et al. · 2025 · Nature Medicine
  6. International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)
    Carmela Aves Caballero, Alexandre Irrthum, Theodora Goulioti, David Cameron, Larry Norton, Martine J Piccart · 2023 · npj Breast Cancer
  7. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world
    Megan Lynn Kruse, Emily Nash Smyth, Lee Bowman, Santosh Gautam, Claudia Morato Guimaraes, Alnecia R Nisbett, Maxine D. Fisher, Zhanglin Lin Cui, Kristin M. Sheffield, Kevin M. Kalinsky · 2023 · Breast Cancer Research and Treatment
  8. Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
    Antonella Ferro, Daniele Generali, Orazio Caffo, Alessia Caldara, Delia De Lisi, Mariachiara Dipasquale, Martina Lorenzi, Sara Monteverdi, Palma Fedele, Yari Ciribilli · 2023 · Seminars in Oncology
  9. Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium
    Mariana Brandão, Diogo Alexandre Martins-Branco, Claudia De Angelis, Peter Vuylsteke, Richard D. Gelber, Nancy Van Damme, Lien van Walle, Arlindo Rebelo Ferreira, Matteo Lambertini, Francesca Benedetta Poggio et al. · 2023 · Breast Cancer Research and Treatment
  10. First‐line CDK4/6 inhibitor‐based combinations for HR+/HER2– advanced breast cancer: A Bayesian network meta‐analysis
    Xianan Guo, Yunxiang Zhou, Kun Zhang, Wei Lü, Xi Zoë Zhong, Shijie Wu, Lu Shen, Huihui Chen, Yiding Chen · 2023 · Journal of Evidence-Based Medicine
  11. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
    Helena Pla, Eudald Felip, Verónica Obadía, Sònia Pernas, Gemma Viñas, Mireia Margelí Vila, Roser Fort‐Culillas, Sonia Del Barco, Nuria Sabaté, Eduard Fort Casamartina et al. · 2024 · Clinical & Translational Oncology
  12. Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?
    Tine Ottenbourgs, Els Van Nieuwenhuysen · 2024 · Cancers
  13. Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4 /6 inhibitor in advanced breast cancer
    Charlotte K. Kindt, Carla L. Alves, Sidse Ehmsen, Amalie Kragh, Thomas Reinert, Marianne Vogsen, Annette Raskov Kodahl, Jeanette Dupont Rønlev, Dilan Ardik, Anna Lahn Sørensen et al. · 2024 · International Journal of Cancer
  14. Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
    Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, Huanaoyu Yang, Linhu Shen, Sikai Feng, Wenjian Min, Kai Yuan, Peng Yang · 2025 · Chinese Journal of Natural Medicines
  15. Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors
    Yeonjoo Choi, Jiayi Tan, David T S Lin, Jin Sun Lee, Yuan Yuan · 2025 · International Journal of Molecular Sciences
  16. Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
    Chiara Corti, Hope S. Rugo, Sara M. Tolaney · 2025 · American Society of Clinical Oncology Educational Book
  17. SAGAN: A Subgraph-Aware Graph Attention Network for Drug Repositioning
    Xiangmao Meng, Xinqiang Wen, Xinliang Sun, Ju Xiang, Yahui Long, Xuan Lin, Min Li · 2025 · Tsinghua Science & Technology
  18. Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1- Mutant Metastatic Breast Cancer
    Maxwell Roger Lloyd, Caroline M. Weipert, Azka Ali, Sheila R. Solomon, Jayati Saha, Marla D. Lipsyc-Sharf, Erika Paige Hamilton, Kevin M. Kalinsky, Adam Brufsky, Aditya Bardia et al. · 2025 · Clinical Cancer Research
  19. Patient-Derived Breast Cancer Bone Metastasis In Vitro Model Using Bone-Mimetic Nanoclay Scaffolds
    Haneesh Jasuja, Farid Solaymani Mohammadi, Jiha Kim, Anu G. Gaba, Dinesh R. Katti, Kalpana S. Katti · 2023 · Journal of Tissue Engineering and Regenerative Medicine
  20. Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
    Federica Villa, Alessandra Crippa, Davide Pelizzoni, Alessandra Ardizzoia, Giulia Scartabellati, Cristina Corbetta, Eleonora Cipriani, Marialuisa Lavitrano, Antonio Ardizzoia · 2023 · International Journal of Molecular Sciences
  21. Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series
    Benjamin B. Albright, Stephanie Shuey, Angeles Alvarez Secord, Laura Jean Havrilesky, Andrew Berchuck, Rebecca A. Previs · 2023 · Gynecologic Oncology Reports
  22. Sequential 2.5 mg letrozole/FSH therapy is more effective for promoting pregnancy in infertile women with PCOS: a pragmatic randomized controlled trial
    Lijuan Chen, Yi Liu, Ling Zhang, Jingyi Li, Wen-Qian Xiong, Tao Li, Hui Ding, Bingjie Li · 2024 · Frontiers in Endocrinology
  23. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
    Elizabeth Magno, Karen M. Bussard · 2024 · International Journal of Molecular Sciences
  24. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
    Alexandre Giraudo, Renaud Sabatier, Frédérique Rousseau, Alexandre Tassin de Nonneville, Anthony Gonçalvès, Maud Cécile, Cécile Braticevic, F. Viret, Lorène Seguin, Maria Kfoury et al. · 2024 · Cancers
  25. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
    Andreas Schneeweiss, Sara Yvonne Brucker, Hanna Huebner, Lea Louise Volmer, Carolin C. Hack, Katharina Seitz, Matthias Ruebner, Sabine Heublein, Verena Thewes, Diana Lüftner et al. · 2024 · Geburtshilfe und Frauenheilkunde
  26. The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials
    Wenqi Zhou, Yeli Yue, Jing Xiong, Wei Li, Xiaohua Zeng · 2024 · Cancer Treatment Reviews
  27. Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial
    John F.R. Robertson, Zhimin Shao, Shinzaburo Noguchi, Igor Bondarenko, Lawrence Panasci, Sandeep R. Singh, Shankar Subramaniam, Matthew J. Ellis · 2025 · Journal of Clinical Oncology
  28. Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
    Bahriye Aktas, Tanja Natascha Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter Andreas Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel et al. · 2022 · Geburtshilfe und Frauenheilkunde
  29. Breast cancer: The good, the bad, and an important call to effective risk reduction strategies
    Virginia Kaklamani, Carlos L. Arteaga · 2024 · CA A Cancer Journal for Clinicians
  30. Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
    Guilherme Nader Marta, Christian Fridolin Singer, Dominik Hlauschek, Angela M. DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martı́n, Justin Micah Balko, Zbigniew Ireneusz Nowecki et al. · 2024 · Breast Cancer Research
  31. Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
    J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, Javier Pascual, Pablo Tolosa, Cristina Pages, Mónica Cuenca, Ángel Guerrero Zotano · 2025 · Cancer Drug Resistance
  32. The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models
    Giuseppina Roscigno, S. Jacobs, Belén Toledo, Roberto Borea, Gianluca Russo, Francesco Pepe, María José Serrano, Viola Calabrò, Giancarlo Troncone, Roberto Giovannoni et al. · 2025 · Seminars in Cancer Biology
  33. Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
    Wensheng Liu, Feifei Gao, Xue Song · 2025 · Frontiers in Pharmacology
  34. Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition)
    Breast Cancer Expert Committee of the National Quality Control Center for Cancer, Breast Cancer Expert Committee of the China Anti-Cancer Association, Cancer Drug Clinical Research Committee of the China Anti-Cancer Association · 2025 · Cancer Innovation
  35. Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study
    Renata Duchnowska, Katarzyna Soter, Katarzyna Pogoda, Jolanta Smok-Kalwat, Aleksandra Grela-Wojewoda, Karolina Winsko-Szczęsnowicz, Agnieszka Kowalewska-Felczak, Marek Szwiec, Iwona Danielewicz, Joanna Streb et al. · 2025 · The Breast
  36. Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors
    Hassan Izzedine, Rimda Wanchoo, Ruby Sharma, Kenar D. Jhaveri · 2025 · Cancer Treatment Reviews
  37. Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
    Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos Hernando Barcenas, Suzanne A.W. Fuqua, Rachel M. Layman, Debu Tripathy · 2026 · CA A Cancer Journal for Clinicians
  38. Novel targeted therapies and immunological strategies for breast cancer treatment
    Ali Mussa, Mahasin Abdallah Mohammed Hamid, Mustafa Talib, Iletou B. Ehinnou, Anthony J. Bragoli, Khalid Hajissa, Noor Fatmawati Mokhtar, Rohimah Mohamud, Mohammad A. I. Al-Hatamleh, Rosline Hassan · 2026 · Biochemical Pharmacology
  39. Rhabdomyolysis Induced by the Interaction Between Ribociclib and Statins- Case Report and Literature Review
    Omar Badran, Mahmoud Abu Amna, Ilit Turgeman, Gil Bar‐Sela · 2023 · Breast Cancer Targets and Therapy
  40. Outcomes and toxicity of concurrent CDK4 /6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer
    Arnaud Beddok, Victoire Mouren, Paul Henri Cottu, Fatima Laki, Alain Fourquet, Youlia Kirova · 2023 · International Journal of Cancer
  41. Characteristics and prognosis of young breast cancer patients treated in a public comprehensive cancer centre in Brazil: A retrospective cohort study
    Karina Belickas Carreiro, Rodrigo Gonçalves, Bruna Salani Mota, José Maria Soares, Edmund Chada Baracat, José Roberto Filassi · 2023 · Cancer Epidemiology
  42. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
    Adam Brufsky, Xianchen Liu, Benjamin C. Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo · 2023 · Cancers
  43. Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending
    Daniel A. Goldstein, Leonard B. Saltz, Gregory R. Pond, Ian F. Tannock · 2024 · BMJ Oncology
  44. Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study
    Tuğba Önder, Ö. Ateş, İrem Öner, Cengiz Karaçin · 2024 · International Journal of Clinical Oncology
  45. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
    Thomas N. O’Connor, Emily Schultz, Jianxin Wang, Tracey L. O’Connor, Ellis Glenn Levine, Erik S. Knudsen, Agnieszka Katarzyna Witkiewicz · 2024 · Cancers
  46. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
    Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo De Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi et al. · 2024 · npj Breast Cancer
  47. Combination therapy of Lapatinib/Letrozole-based protein-vitamin nanoparticles to enhance the therapeutic effectiveness in drug-resistant breast cancer
    Varshini Are, Sneha Das, P S Shishira · 2024 · Colloids and Surfaces B Biointerfaces
  48. ChatGPT’s Agreement with the Recommendations from the 18th St. Gallen International Consensus Conference on the Treatment of Early Breast Cancer
    Naiba Nabieva, Sara Yvonne Brucker, Benjamin Gmeiner · 2024 · Cancers
  49. Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases
    Ryan K. Rader, Carey K. Anders, NU Lin, Sarah LeNoir Sammons · 2023 · Current Treatment Options in Oncology
  50. Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
    Ángel Guerrero Zotano, José Manuel Pérez-García, Manuel Ruíz‐Borrego, Begoña Bermejo, Miguel Gil‐Gil, J. de la Haba, Emilio Alba, Vanesa Quiroga, Vicente Carañana, Ander Urruticoechea et al. · 2024 · ESMO Open
  51. Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
    Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta et al. · 2024 · Current Oncology
  52. Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
    Trang Huyen Thi Nguyen, Shweta Mital · 2024 · PharmacoEconomics
  53. Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor
    Diego Malón, Consolación Moltó, Shopnil Prasla, Danielle Cuthbert, Neha Pathak, Yael Berner-Wygoda, Massimo Di lorio, Meredith Li, Jacqueline Savill, Abhenil Mittal et al. · 2024 · Breast Cancer Research and Treatment
  54. Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
    Ram Patel, John Mathews, Caroline M. Hamm, Swati Kulkarni, Rasna Gupta, Tarquin Opperman, John Dean Chiong, Abdullah Nasser · 2025 · Current Oncology
  55. A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy
    İrem Öner, Hicran Anık, Bediz Kurt İnci, Pınar Kubilay Tolunay, Öztürk Ateş, Ülkü Yalçıntaş Arslan, Cengiz Karaçin · 2025 · Medicina
  56. Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
    Mashael Algethami, Ahmed Shoqafi, Ayat Lashen, Shatha Alqahtani, Jake Spicer, Ahmad Altayyar, Çağla Tosun, Jennie N. Jeyapalan, Nigel Patrick Mongan, Victoria H. James et al. · 2025 · Scientific Reports
  57. US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
    Suparna Bonthala Wedam, Preeti Narayan, Haley R Gittleman et al. · 2025 · Journal of Clinical Oncology
  58. 600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ ERBB2 -Negative Advanced Breast Cancer
    Fátima Cardoso, William Jacot, Sherko Küemmel, Sudeep Gupta, Felipe Melo Cruz, Rama Balaraman, Ana Filipa Ferreira, Tytti M. Ahola, Чапко Яна Станиславовна, Lyudmila Zhukova et al. · 2025 · JAMA Oncology
  59. Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer
    Emma Zattarin, Antonio Marra, Antonella Palazzo, Gaia Griguolo, Claudio Vernieri, Julian David Etessami, Letizia Pontolillo, Giusy Landa, Arianna Daneri, Matteo De Monte et al. · 2025 · npj Breast Cancer
  60. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review
    Shlomit Strulov Shachar, Yasmin Korzets, Daniel Shepshelovich, Noa Zlothover, Eitan Amir, Ariadna Tibau, Hadar Goldvaser · 2023 · Cancer Treatment Reviews
  61. Racial and survival disparities in inflammatory breast cancer (IBC) and non-IBC: a population-based study focused on Native Hawaiians and other Pacific Islanders
    Gene T. Yoshikawa, Kyle S. Miyazaki, Jared David Acoba · 2024 · Frontiers in Oncology
  62. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China
    Hanfang Jiang, Jianxin Zhong, Jing Wang, Guohong Song, Lijun Di, Bin Shao, Ruyan Zhang, Yaxin Liu, Anjie Zhu, Nan Wang et al. · 2024 · Cancer Medicine
  63. Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
    Andreas Daniel Hartkopf, Christina Barbara Walter, Hans‐Christian Kolberg, Peyman Hadji, Hans Tesch, Peter Andreas Fasching, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller et al. · 2024 · Geburtshilfe und Frauenheilkunde
  64. Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer
    RK Goyal, Sean D. Candrilli, Susan Abughosh · 2024 · Cancers
  65. Enhancing breast cancer treatment through pharmacogenomics: A narrative review
    Ram Mohan Ram Kumar, Suresh Joghee · 2024 · Clinica Chimica Acta
  66. UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer
    Georgina Gullick, C.N. Owen, William John Watkins, Seamus Cook, Jonathan Helbrow, Hannah Reed, R. Squires, SEOK WON PARK, E. Weir, Francesca Aquilina et al. · 2024 · ESMO Real World Data and Digital Oncology
  67. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
    Eugen Ruckhäberle, Marcus Schmidt, Anja Welt, Nadia Harbeck, Achim Wöckel, Oleg Gluz, Tjoung‐Won Park‐Simon, Michael Untch, Michael Patrick Lux · 2024 · Geburtshilfe und Frauenheilkunde
  68. Role of Radiology in the Diagnosis and Treatment of Breast Cancer in Women: A Comprehensive Review
    Muhammad Arslan, Muhammad Asim, Hina Sattar, Anita Khan, Farsina Thoppil Ali, Muneeza Zehra, Keerthi Talluri · 2024 · Cureus
  69. Nanoemulsion‐based transdermal delivery of third‐generation steroidal and non‐steroidal aromatase inhibitors in preclinical models
    Lanyang Gao, Lin Gao, Shiyao Huang, Lei Sun, Mei Li, Chen Shen, Youyou Chen, Ruihao Tan, Yuji Chen, Chengguo Zhan et al. · 2024 · Cell Proliferation
  70. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
    Francis Paul Worden, Evan P. Pisick, Michael Rothe, Pam K. Mangat, Elizabeth S. Garrett-Mayer, Maged F. Khalil, Daniel Ricardo Carrizosa, Jessica Ruth Bauman, Rom S. Leidner, Herbert Leon Duvivier et al. · 2024 · JCO Precision Oncology
  71. Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study
    Belinda Sassé, Sammy Shaya, Jessica Nimmo et al. · 2024 · The Breast
  72. Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer
    Wolfgang J. Janni, Hans‐Christian Kolberg, Andreas Daniel Hartkopf, Tanja Natascha Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter Andreas Fasching, Christian Jackisch, Frederik Marmé et al. · 2025 · Geburtshilfe und Frauenheilkunde
  73. Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
    Simona Borštnar, Markéta Palácová, Aleksandra Łacko, Constanta V. Timcheva, Einav Nili Gal‐Yam, Konstantinos T Papazisis, Juraj Beniak, Pavol Kudela, Gábor Rubovszky · 2022 · Radiology and Oncology
  74. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
    Taronish D. Dubash, Aditya Bardia, Brian Chirn, Brittany A. Reeves, Joseph A. LiCausi, Risa Burr, Ben S. Wittner, Sumit Rai, Hitisha Patel, Teeru Bihani et al. · 2023 · Breast Cancer Research and Treatment
  75. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
    Kristin Wright, Abhenil Mittal, Bishal Gyawali · 2023 · Current Opinion in Oncology
  76. Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study
    Daniele Xavier Assad, Alessandra Menezes Morelle, Mayana Lopes de Brito, Flavia Rocha Paes, André P. L. Mattar, Jorge Henrique Santos Leal, Sergio Daniel Simon, Ellias Magalhães Abreu Lima, Gustavo Werutsky, Gustavo Henrique Munhoz Piotto et al. · 2024 · JCO Global Oncology
  77. Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
    Martina Perrone, Francesco Giuliani, Valeria Sanna, Stefania Bruno, Assunta Melaccio, Anna Natalizia Santoro, Carmelo Laface, Felicia Maria Maselli, Maria Laura Iaia, Chiara Guarini et al. · 2023 · Expert Opinion on Pharmacotherapy
  78. Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives
    Filippo Merloni, Michela Palleschi, Caterina Gianni, Marianna Sirico, Riccardo Serra, Chiara Casadei, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Marita Mariotti et al. · 2024 · Clinical & Experimental Metastasis
  79. Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
    Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang et al. · 2025 · Nature Communications
  80. Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
    Hope S. Rugo, Aditya Bardia, William John Gradishar, Erika Paige Hamilton, Sara Alsterlind Hurvitz, Komal L. Jhaveri, Reshma L Mahtani, Sara M. Tolaney · 2025 · The Breast
  81. Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
    Roberta Scafetta, Marco Donato, Chiara Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Raffaella Troiano, Simone Foderaro, Valentina Ricozzi et al. · 2025 · The Breast
  82. Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer
    Diana Lüftner, Hans‐Christian Kolberg, Andreas Daniel Hartkopf, Tanja Natascha Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter Andreas Fasching, Christian Jackisch, Frederik Marmé et al. · 2025 · Geburtshilfe und Frauenheilkunde
  83. Management of Metastatic Hormone Receptor-Positive Breast Cancer Beyond CDK4/6 Inhibitors
    Philip D. Tracy, Emily Bopp, Emily M. Milner, Ana Christina Garrido-Castro, Antonio Giordano, Erica L. Mayer, Sara M. Tolaney, Paolo Tarantino, Ilana Miriam Schlam · 2025 · Current Oncology Reports
  84. Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial
    A. Llombart-Cussac, J.M. Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel Gil‐Gil, Manuel Ruíz‐Borrego, J.G. Gavila, Peter Schmid, Pilar M. Zamora, Duncan A. Wheatley et al. · 2025 · ESMO Open
  85. Navigating liver toxicity in the age of novel oncological agents
    Mar Riveiro‐Barciela, Eléonora De Martin · 2025 · JHEP Reports
  86. Discovery of pyrazolo[1,5-a]pyrimidines: Synthesis, in silico insights, and anticancer activity via novel CDK2/Tubulin dual inhibition approach
    Hossam R. Elgiushy, Mahmoud E. Soliman, Mohamed E. El‐Khouly, Khaled A. M. Abouzid, Sherif Hammad · 2025 · Bioorganic Chemistry
  87. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
    Richard D. Baird, Begoña Bermejo, Manuel Ruíz-Borrego, Christos Vaklavas, Irene Moreno, Mafalda Oliveira, Anne Caroline Armstrong, Nicholas C. Turner, Jason Incorvati, Chris J. Twelves et al. · 2025 · Clinical Cancer Research
  88. Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors
    Uriel Kim, Thomas S. McCormick, Ankit Mangla, Kevin D. Cooper, Gary K. Schwartz, Akihiro Yoshida · 2025 · Pharmacological Research
  89. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis
    Yuan Liu, Tongtong Ren, Chen Xu, Qinglan He, Xinchun Wang, Lisha Tang · 2025 · BMC Cancer
  90. Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies
    Dana P. Narvaez, David W. Cescon · 2025 · International Journal of Molecular Sciences
  91. Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer – A systematic review and meta-analysis
    Yee Yin Hoo, Wei-Wei Sia, Sharminii Jaya-Prakason, Bogda Koczwara, Yek‐Ching Kong, Joe‐Elie Salem, Agnès Dechartres, Nirmala Bhoo‐Pathy · 2025 · Cancer Treatment Reviews
  92. Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA -mutant breast cancer
    Carla L. Alves, Leena Karimi, Mikkel G. Terp, Mie K. Jakobsen, Fiona H. Zhou, Benedetta Policastro, Nikoline Nissen, Lene E. Johansen, Tina Ravnsborg, Leila Eshraghi et al. · 2025 · Science Translational Medicine
  93. The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions
    Carmelo Laface, Francesco Giuliani, Assunta Melaccio, Maria Nicla Pappagallo, Anna Natalizia Santoro, Martina Perrone, Pierluigi De Santis, Chiara Guarini, Daniela Carrozzo, Palma Fedele · 2023 · Journal of Clinical Medicine
  94. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
    Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani et al. · 2023 · Therapeutic Advances in Medical Oncology
  95. Ribociclib plus Endocrine Therapy in Early Breast Cancer
    Hengjia Tu, Yuzhuo Zhang, Zhixuan You · 2024 · New England Journal of Medicine
  96. Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
    Rodrigo Sánchez-Bayona, Mafalda Oliveira · 2024 · Annals of Oncology
  97. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine
    Jelena Dinić, Sofija Jovanović Stojanov, Miodrag Dragoj, Marija Grozdanić, Ana Podolski-Renić, Milica Pešić · 2024 · Life
  98. Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer
    Nicole L Brown, Ann Tivey, Suzanne Frank, Siow Chin Phua, Jack E. Johnson, Anne Caroline Armstrong, Caroline Wilson, Sophie Raby, Sophie Low, Yvonne Hulmes et al. · 2024 · Clinical Breast Cancer
  99. Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
    Hui‐Chen Su, Ho-Wei Lin, Ka‐Wai Tam · 2024 · Targeted Oncology
  100. Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors
    Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra · 2025 · Current Oncology